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EDITORIAL COMMENT
Primary Prevention of
Sudden Death Using ICD
Therapy: Incremental Steps*
Alan Kadish, MD, FACC
Chicago, Illinois
Ever since its development by Dr. Michel Mirowski in the
1970s and its use in clinical practice in 1980, the implant-
able cardioverter-defibrillator (ICD) has improved survival
in patients presenting with sustained ventricular tachycardia
and ventricular fibrillation. Three recent randomized stud-
ies—Antiarrhythmic Drugs versus Implantable Defibrillator
(AVID) (1), Canadian Implantable Defibrillator Study
(CIDS) (2) and Cardiac Arrest Study Hamburg (CASH)
(3)—have demonstrated that the ICD is superior to the best
antiarrhythmic therapy in the prevention of death in pa-
tients who have already experienced an episode of sustained
tachycardia arrhythmia. Although sub-analysis of AVID
and CIDS data has suggested that antiarrhythmic drug
therapy may be as good as ICD therapy in patients with
relatively well-preserved ventricular function, this result
remains to be confirmed prospectively (4), and ICD therapy
remains the most efficacious therapy in the secondary
prevention of sudden death (SD). However, because only a
small percentage of patients who suffer a cardiac arrest in the
U.S. each year survive to benefit from ICD therapy as
secondary prevention, the use of the ICD for the primary
prevention of SD has received increasing attention.
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Prior studies. Four prospective studies have been com-
pleted in which the use of the ICD in the primary
prevention of SD was evaluated. The final results of three of
these studies have been published in manuscript form. In
the CABG (Coronary Artery Bypass Graft) patch study (5),
epicardial ICDs were not found to be a useful adjunct to
bypass surgery. However, given the selected nature of the
patient population and the changes in ICD technology,
these results do not have a major impact on clinical practice
today. The Multicenter Automatic Defibrillator Implanta-
tion Trial (6) and Multicenter Unsustained Tachycardia
Trial (7) studies evaluated use of the ICD in the primary
prevention of SD in patients with ischemic heart disease,
left ventricular dysfunction and inducible sustained ventric-
ular tachycardia. In both these studies, a dramatic survival
benefit of the ICD was noted, and the Food and Drug
Administration has approved the ICD for this indication.
The AMIOVIRT study, which has been reported only in
preliminary form, was a partially randomized, partially
uncontrolled observational study of patients with non-
ischemic cardiomyopathy at risk for SD (8). In this study,
amiodarone and the ICD were equally effective or ineffective
at preventing death (no control group was used), but the
small size of the study limited its power to detect moderate
beneficial effects of the ICD.
The pathophysiology and incidence of SD in patients
with ischemic and non-ischemic cardiomyopathy may differ
somewhat. Because therapy for coronary artery disease is
widely variable among different trials and has changed
drastically over the past decade, differences in survival
depending on the type of underlying heart disease are
somewhat difficult to evaluate with certainty. Most heart
failure trials have not been adequately powered to detect
differences in survival between patients with different kinds
of ischemic and non-ischemic cardiomyopathy. Studies
using intra-operative mapping suggest that, whereas ven-
tricular tachycardia in patients with coronary disease is often
reentrant, the initiation of tachy-arrhythmias in patients
with non-ischemic cardiomyopathy is almost invariably
focal.
These studies suggest that the mechanism of SD and
predictors of survival may differ in patients with coronary
artery disease and those with non-ischemic cardiomyopathy,
suggesting that clinical data on each type of structural heart
disease are needed.
New findings. Thus, the results of the study by Grimm et
al. (10) have potential importance. These investigators
compared the incidence of appropriate shocks in 49 pa-
tients, in whom the ICD was implanted prophylactically,
with 26 patients who presented with syncope and with 26
others who presented with sustained ventricular tachycardia
or ventricular fibrillation. The incidence of appropriate
shocks was similar in each of the groups, but using multi-
variate analysis, the presence of sustained ventricular tachy-
cardia/ventricular fibrillation was a predictor of appropriate
ICD shocks. Nonetheless, 37% of the patients who received
the ICD for the primary prevention of SD (left ventricular
ejection fraction 0.30 and non-ischemic cardiomyopathy)
had appropriate ICD shocks.
Study limitations. Some limitations to the study should be
noted. One difficulty in evaluating either retrospective or
prospective studies on primary prevention of SD in heart
failure is the changing survival due to advances in medical
therapy. Improvements in the therapy of heart failure, such
as angiotensin-converting enzyme (ACE) inhibitors and
beta-blockers, have dramatically increased survival in pa-
tients with both ischemic and non-ischemic cardiomyopa-
thy. Of particular relevance to the results of this study, a
dramatic survival improvement in patients with heart failure
treated with beta-blockers was noted in the late 1990s and
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was surprisingly large in several trials (30% to 35%) (11,12).
Although the frequency of use of ACE inhibitors was
admirable in the present study, only one-third of patients
were treated with beta-blockers. Had a substantially higher
percentage of patients been treated with beta-blockers, the
results might have demonstrated a lower incidence of
appropriate ICD shocks. The use of ICD shocks as a
surrogate for improvements in clinical outcome even in
devices with electrogram recall also has some limitations.
Even with electrogram recall, some ICD shocks, especially
those from single-chamber devices, may be misclassified. In
addition, even if the ventricular tachy-arrhythmia is appro-
priately detected, some arrhythmias that occurred sponta-
neously may terminate before causing adverse clinical out-
come.
The results in 26 patients in whom ICDs were implanted
for syncope in nonischemic cardiomyopathy are also inter-
esting but somewhat difficult to interpret. A substantial
percentage of patients presenting with syncope had appro-
priate ICD discharges. However, the incidence was not
different from the incidence in patients in whom the ICDs
were implanted for the primary prevention of SD. The
ejection fraction in patients with syncope was somewhat
higher than in those in whom the ICD was implanted for
primary prevention, but the number of patients with syn-
cope in whom the ejection fraction was not 0.3 was not
reported and is not likely to be large enough for any
independent conclusions to be drawn. Thus, whether syn-
cope alone should represent an incremental indication for
ICD therapy is not clear from the present study.
Despite these limitations, the present report represents a
large series of patients with non-ischemic cardiomyopathy
who underwent ICD implantation for the primary preven-
tion of SD. Although background medical therapy and the
retrospective nature of this study mitigate against drawing
sweeping conclusions, the results do suggest that further
research on ICD therapy for the primary prevention of SD
in patients with non-ischemic cardiomyopathy is needed.
Two currently ongoing trials that have completed or nearly
completed enrollment—the SCD-Heft Trial and the
DEFINITE Trials (13)—should help define whether the
ICD should have a role in the primary prevention of SD in
patients with non-ischemic cardiomyopathy, as it currently
does in patients with ischemic heart disease.
It should also be noted that prophylactic implantation of
an ICD is not the only or even perhaps the most cost-
effective therapy that should be directed at the primary
prevention of SD. Therapy to prevent structural heart
disease, an improved understanding of which neuro-
humoral factors contribute to the risk of SD in heart failure,
improvements in CPR, bi-ventricular pacing, and more
widespread use of the automatic external defibrillator are all
likely to have a role—along with the ICD—in preventing
SD.
Reprint requests and correspondence: Dr. Alan Kadish, Profes-
sor of Medicine, Northwestern University, 251 East Huron Street,
Suite 8-536, Chicago, Illinois 60611.
REFERENCES
1. The AVID investigators. A comparison of antiarrhythmic drug ther-
apy with implantable defibrillatiors in patients resuscitated from
near-fatal sustained ventricular arrhythmias. N Engl J Med 1997;337:
1576–83.
2. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable
Defibrillator Study (CIDS): a randomized trial of the implantable
cardioverter-defibrillator against amiodarone. Circulation 2000;101:
1297–302.
3. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison
of antiarrhythmic drug therapy with implantable defibrillators in
patients resuscitated from cardiac arrest: the Cardiac Arrest Study
Hamburg (CASH). Circulation 2000;102:748–54.
4. Hallstrom AP, McAnulty JH, Wilkoff BL, et al. Antiarrhythmics
Versus Implantable Defibrillator Trial I. Patients at lower risk of
arrhythmia recurrence: a subgroup in whom implantable defibrillators
may not offer benefit. Antiarrhythmics Versus Implantable Defibril-
lator (AVID) Trial investigators. J Am Coll Cardiol 2001;37:1093–9.
5. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in
patients at high risk for ventricular arrhythmias after coronary-artery
bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch
Trial investigators. N Engl J Med 1997;337:1569–75.
6. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an
implanted defibrillator in patients with coronary disease at high risk for
ventricular arrhythmia. Multicenter Automatic Defibrillator Implan-
tation Trial Investigators. N Engl J Med 1996;335:1933–40.
7. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN,
Hafley G. A randomized study of the prevention of sudden death in
patients with coronary artery disease. Multicenter Unsustained Tachy-
cardia Trial investigators [erratum appears in N Engl J Med 2000;
342:1300]. N Engl J Med 1999;341:1882–90.
8. Strickberger S. AMIOVIRT (Amiodarone vs. Implantable Defibril-
lator in Patients with non-Ischemic Cardiomyopathy and Asymptom-
atic non-Sustained Ventricular Tachycardia) (abstr). Clin Cardiol
2001;24:87.
9. Pogwizd SM, McKenzie JP, Cain ME. Mechanisms underlying
spontaneous and induced ventricular arrhythmias in patients with
idiopathic-dilated cardiomyopathy. Circulation 1998;98:2404–14.
10. Grimm W, Hoffmann J, Hans-Helge M, Maisch B. Implantable
defibrillator event rates in patients with idiopathic dilated cardiomy-
opathy, nonsustained ventricular tachycardia on Holter and a left
ventricular ejection fraction below 30%. J Am Coll Cardiol 2002;39:
780–7.
11. MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure:
Metoprolol CR/XL Randomized Intervention Trial in Congestive
Heart Failure. Lancet 1999;353:2001–7.
12. Anonymous. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-
II): a randomised trial. Lancet 1999;353:9–13.
13. Kadish A, Quigg R, Schaechter A, Anderson KP, Estes M, Levine J.
Defibrillators in nonischemic cardiomyopathy treatment evaluation.
Pacing Clin Electrophysiol 2000;23:338–43.
789JACC Vol. 39, No. 5, 2002 Kadish
March 6, 2002:788–9 Editorial Comment
